FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

TIES AND EXCHANGE COMMIS

OMB APPROVAL								
OMB Number:	3235-0287							

0.5

Footnote⁽²⁾

Footnote⁽²⁾

Footnote⁽²⁾

See

I

Estimated average burden hours per response:

5. Relationship of Reporting Person(s) to Issuer

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person*

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name **and** Ticker or Trading Symbol

NATIXIS PRIVATE EQUITY					EYEGATE PHARMACEUTICALS INC [EYEG]							Crieck	Director	ŕ	X	10% Ov	
(Last) (First) (Middle) 5-7 RUE DE MONTTESSUY					3. Date of Earliest Transaction (Month/Day/Year) 02/19/2015					-	Officer (gi below)	ive title		Other (s below)	pecity		
(Street) PARIS (City)	I()) State)	75007 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Indiv	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
			Table I - Non	-Deriva	ative	Securiti	es Acq	uired,	Dis	oosed of, o	or Bene	ficially O	wned				
Da			Date	nth/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		ction Instr.	4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a		A) or , 4 and 5)	5. Amount o Securities Beneficially Following R	Owned eported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)					
Common Stock 02			02/19/	9/2015			С		576,564	A	(1)	576,564			I I	See Footnote ⁽²⁾	
Common Stock 02/19				02/19/	.9/2015			С		97,641	A	\$4.2	674,205		I		See Footnote ⁽²⁾
										osed of, or onvertible			med				<u> </u>
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Code (Instr. r) 8)		Derivative Securities (A) or Dis	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		te Exer ation E th/Day		7. Title an of Securit Underlyin Derivative (Instr. 3 a	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Numb derivati Securiti Benefic Owned	ive Ow ies For cially Dir	10. Ownership Form: Direct (D) or Indirect	Beneficial Ownership (Instr. 4)
	Security			Code	v	(A) (D)		Date Expire		Expiration Date	Title	Amount or Number of Shares		Followi Report Transa (Instr. 4	ed ction(s)	(I) (Instr. 4	,

Explanation of Responses:

(1)

\$4.2

\$4.2

02/19/2015

02/19/2015

02/19/2015

1. Upon closing of the Issuer's initial public offering, each share of Series D Preferred Stock converted automatically into shares of Common Stock of the Issuer on a 10.96-for-one basis, and had no expiration date.

\$410,092

576,564

\$410,092

(1)

02/19/2015

02/19/2015

(1)

06/06/2015

06/06/2015

2. Represents shares and warrants held by NPE Coinvest ("NC"). Natxis Private Equity ("NPE") owns 100% of NC. NPE disclaims beneficial ownership of these securities and this report shall not be deemed an admission that NPE is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of its pecuniary interest therein. Voting and investment power over the shares held by NC may be deemed to be shared with NPE due to its parent relationship. Each of Dominique Sabassier ("Sabassier") and Cyrille Marcilhacy ("Marcilhacy ") are officers of NPE. Each of Sabassier and Marcilhacy disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein.

Remarks:

Series D

Preferred

Stock Convertible

Note Convertible

Note

Promissory

*Signed under power of attorney on behalf of Reporting Person

/s/ Authorized Signatory* 02/23/2015

** Signature of Reporting Person Date

576,564

97,641

97,641

Stock

Commor

Stock

Commor

\$<mark>0</mark>

\$410,092

\$0

\$410,092

0

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

C

C

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.